logo supramedic



The main goal of SUPRAMED is to establish an interdisciplinary research programme in Spain based on Supramolecular Medicinal Chemistry. The group’s research will be focused on the generation and characterization of new compounds with anti-parasitic, anti-inflammatory or anti-tumourigenic activity that could be developed into therapeutic agents. There is growing evidence that nitrogenated organic compounds, as well as their metal complexes have therapeutic potential in human pathologies involving superoxide production. We have already produced and performed a preliminarily characterization of several families of nitrogenated organic compounds, as well as of a variety of their metal complexes with MnII, FeIII/FeII, CuI/CuII and ZnII. The aim of this proposal is to provide a suitable framework to develop a competitive and high-quality research consortium focused on:


Clic here if you can't watch the video

  • Design, synthesis and characterization of biomedically relevant molecules with anti-parasitic activity. Encouragingly, some of these water soluble compounds efficiently combat the protozoa that cause Chagas disease and leishmaniasis in preliminary in vivo assays in mice with a ten times lower toxicity than the commercial drugs currently used to treat these worldwide parasitic diseases that affect millions of people.

  • Synthesis and screening of new molecules as enzymatic mimetics with anti-inflammatory activity. In addition we aim to pursue new series of related molecules containing polyamine, polyamide, mixed amine-amide, oligosquaramide, triazolopyridine, pyrazole, imidazole, phthalazine and benzo[g]phthalazine moieties, and organic receptors able to form mononuclear Fe and Mn, as well as mixed binuclear Cu-Zn coordination compounds, to reproduce features of the active sites of dioxygen protective enzymes.

  • Design, synthesis and study of the interaction with nucleic acids and oxygen species with anti-tumoural activity. The mechanism underlying the interactions with nucleic acids and oxygen species will be examined, and the results used to redefine the synthetic aspects. The antioxidant activity of the receptors and complexes prepared will be systematically tested. In addition, metal complexes (Fe, Cu, Mn) capable of activating O2 and containing polyamino acid chains as sequence selective DNA and/or RNA recognition units will be prepared and studied. Such compounds are designed as DNA and/or RNA sequence selective oxidative degradation metallodrugs. From the results of these analyses, compounds will be checked for anti-inflammatory and/or anti-proliferative (anti-tumorougenic) activity in cell cultures in vitro, and the most promising ones will also be checked in vivo in animal models of inflammation and/or cancer.

  • To support and organize molecules on nanoparticles. The receptors showing the most outstanding characteristics will be attached to inorganic oxidic nanoparticles, using structures of increasing complexity in order to amplify responses and to improve the taxiing of the compound to a target tissue or organ.

Thus, this project pretends to combine the synthetic capabilities of organic/inorganic chemists and molecular theoretical studies with the capacity to evaluate the anti-inflammatory, anti-tumour and anti-parasitic activity developed by the groups with medical and biological background in order to design new therapeutic agents. Moreover, the consortium established will clearly offer interesting opportunities from the point of view of training researchers in the field of Supramolecular Medicinal Chemistry.

© 2011